Active	Status	Sponsor type	Region	Phase	Filter
11 Active 3 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Badalamenti, Giuseppe
TANGENT, NCT05417789: Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)	Recruiting	3	128	Europe, Canada, US, RoW	Emactuzumab, Placebo	SynOx Therapeutics Limited	TGCT	04/26	09/27
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma	Recruiting	2	201	Europe, US, RoW	INBRX-109, Placebo	Inhibrx Biosciences, Inc	Conventional Chondrosarcoma	09/25	12/26
ERASING, NCT03840772 / 2018-004571-12: Eribulin in Advanced Solitary Fibrous Tumor	Completed	2	16	Europe	Eribulin, Intervention under investigation	Italian Sarcoma Group, Eisai Inc.	Solitary Fibrous Tumor	09/24	09/24
ACCeSs, NCT04274023 / 2016-004368-21: Study on TSR-042 in Advanced Clear Cell Sarcoma	Terminated	2	3	Europe	TSR-042	Italian Sarcoma Group, GlaxoSmithKline	Sarcoma, Clear Cell	01/24	01/24
ISG-MCS, NCT04305548 / 2019-003733-41: Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma	Recruiting	2	16	Europe	Trabectedin	Italian Sarcoma Group, PharmaMar	Mesenchymal Chondrosarcoma	08/25	12/25
TOMAS2, NCT03838744 / 2018-004497-10: Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.	Completed	2	130	Europe	Standard arm: Trabectedin in monotherapy, Trabectedin arm, Experimental arm: Trabectedin + Olaparib, Trabectedin+ Olaparib arm	Italian Sarcoma Group, PharmaMar, AstraZeneca	Advanced Soft Tissue Sarcoma	11/24	11/24